Near-diploidy: A new prognostic factor for clinically localized prostate cancer treated with external beam radiation therapy

Alan Pollack, G. K. Zagars, A. K. El-Naggar, M. D. Gauwitz, N. H A Terry

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Background. DNA ploidy is a significant prognostic factor in patients with prostate cancer. Using DNA/nuclear protein flow cytometry, a subpopulation of tumors with near-diploid DNA is identifiable. The prognostic significance of near-diploidy was examined. Methods. Paraffin-embedded formalin fixed prostate tumor tissue from patients treated at M. D. Anderson Cancer Center with external beam radiation therapy was processed for DNA/nuclear protein flow cytometry. All patients had pretreatment and follow-up serum prostate specific antigen (PSA) levels. Seventy-six specimens were suitable for flow cytometric analysis. Tumors were classified as either diploid (n = 30), near- diploid (n = 24), or nondiploid (n = 22, tetraploid and aneuploid). Median follow-up time was 36 months. Results. Diploid tumors were associated with a significantly better actuarial outcome at 4 years, compared with near- diploid tumors, using either biochemical relapse (rising PSA) or a composite end point of a rising PSA or clinical relapse (16% versus 52% relapse, P < 0.05, log-rank). Moreover, patients who had nondiploid tumors had the worst prognosis (77% relapse, composite end point). No significant difference was observed between diploid and near-diploid neoplasms regarding actuarial local control, freedom from metastasis, freedom from clinical relapse, or overall survival time. A Cox proportional hazards model, using the composite end point of a rising PSA or relapse, was performed with ploidy categorized as diploid, near-diploid, and nondiploid: pretreatment PSA, DNA ploidy, and tumor grade were found to be independent prognostic factors. When ploidy was categorized as diploid or near-diploid (nondiploid tumors excluded), pretreatment serum PSA and DNA ploidy were independent predictors of outcome. Ploidy remained an independent prognostic factor even when nondiploid tumors were excluded. Conclusions. These data show that patients who have near- diploid tumors have an intermediate prognosis between the more favorable diploid tumors and the less favorable nondiploid tumors.

Original languageEnglish
Pages (from-to)1895-1903
Number of pages9
JournalCancer
Volume73
Issue number7
StatePublished - Jan 1 1994
Externally publishedYes

Fingerprint

Diploidy
Prostatic Neoplasms
Radiotherapy
Ploidies
Prostate-Specific Antigen
Neoplasms
Recurrence
DNA
Nuclear Proteins
Flow Cytometry
Tetraploidy
Aneuploidy
Serum
Proportional Hazards Models
Paraffin
Formaldehyde
Prostate

Keywords

  • DNA
  • flow cytometry
  • nuclear protein
  • ploidy
  • prostate cancer
  • radiation therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Pollack, A., Zagars, G. K., El-Naggar, A. K., Gauwitz, M. D., & Terry, N. H. A. (1994). Near-diploidy: A new prognostic factor for clinically localized prostate cancer treated with external beam radiation therapy. Cancer, 73(7), 1895-1903.

Near-diploidy : A new prognostic factor for clinically localized prostate cancer treated with external beam radiation therapy. / Pollack, Alan; Zagars, G. K.; El-Naggar, A. K.; Gauwitz, M. D.; Terry, N. H A.

In: Cancer, Vol. 73, No. 7, 01.01.1994, p. 1895-1903.

Research output: Contribution to journalArticle

Pollack, A, Zagars, GK, El-Naggar, AK, Gauwitz, MD & Terry, NHA 1994, 'Near-diploidy: A new prognostic factor for clinically localized prostate cancer treated with external beam radiation therapy', Cancer, vol. 73, no. 7, pp. 1895-1903.
Pollack, Alan ; Zagars, G. K. ; El-Naggar, A. K. ; Gauwitz, M. D. ; Terry, N. H A. / Near-diploidy : A new prognostic factor for clinically localized prostate cancer treated with external beam radiation therapy. In: Cancer. 1994 ; Vol. 73, No. 7. pp. 1895-1903.
@article{3f777b9858c148a4b15a7aabd2e4c43b,
title = "Near-diploidy: A new prognostic factor for clinically localized prostate cancer treated with external beam radiation therapy",
abstract = "Background. DNA ploidy is a significant prognostic factor in patients with prostate cancer. Using DNA/nuclear protein flow cytometry, a subpopulation of tumors with near-diploid DNA is identifiable. The prognostic significance of near-diploidy was examined. Methods. Paraffin-embedded formalin fixed prostate tumor tissue from patients treated at M. D. Anderson Cancer Center with external beam radiation therapy was processed for DNA/nuclear protein flow cytometry. All patients had pretreatment and follow-up serum prostate specific antigen (PSA) levels. Seventy-six specimens were suitable for flow cytometric analysis. Tumors were classified as either diploid (n = 30), near- diploid (n = 24), or nondiploid (n = 22, tetraploid and aneuploid). Median follow-up time was 36 months. Results. Diploid tumors were associated with a significantly better actuarial outcome at 4 years, compared with near- diploid tumors, using either biochemical relapse (rising PSA) or a composite end point of a rising PSA or clinical relapse (16{\%} versus 52{\%} relapse, P < 0.05, log-rank). Moreover, patients who had nondiploid tumors had the worst prognosis (77{\%} relapse, composite end point). No significant difference was observed between diploid and near-diploid neoplasms regarding actuarial local control, freedom from metastasis, freedom from clinical relapse, or overall survival time. A Cox proportional hazards model, using the composite end point of a rising PSA or relapse, was performed with ploidy categorized as diploid, near-diploid, and nondiploid: pretreatment PSA, DNA ploidy, and tumor grade were found to be independent prognostic factors. When ploidy was categorized as diploid or near-diploid (nondiploid tumors excluded), pretreatment serum PSA and DNA ploidy were independent predictors of outcome. Ploidy remained an independent prognostic factor even when nondiploid tumors were excluded. Conclusions. These data show that patients who have near- diploid tumors have an intermediate prognosis between the more favorable diploid tumors and the less favorable nondiploid tumors.",
keywords = "DNA, flow cytometry, nuclear protein, ploidy, prostate cancer, radiation therapy",
author = "Alan Pollack and Zagars, {G. K.} and El-Naggar, {A. K.} and Gauwitz, {M. D.} and Terry, {N. H A}",
year = "1994",
month = "1",
day = "1",
language = "English",
volume = "73",
pages = "1895--1903",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "7",

}

TY - JOUR

T1 - Near-diploidy

T2 - A new prognostic factor for clinically localized prostate cancer treated with external beam radiation therapy

AU - Pollack, Alan

AU - Zagars, G. K.

AU - El-Naggar, A. K.

AU - Gauwitz, M. D.

AU - Terry, N. H A

PY - 1994/1/1

Y1 - 1994/1/1

N2 - Background. DNA ploidy is a significant prognostic factor in patients with prostate cancer. Using DNA/nuclear protein flow cytometry, a subpopulation of tumors with near-diploid DNA is identifiable. The prognostic significance of near-diploidy was examined. Methods. Paraffin-embedded formalin fixed prostate tumor tissue from patients treated at M. D. Anderson Cancer Center with external beam radiation therapy was processed for DNA/nuclear protein flow cytometry. All patients had pretreatment and follow-up serum prostate specific antigen (PSA) levels. Seventy-six specimens were suitable for flow cytometric analysis. Tumors were classified as either diploid (n = 30), near- diploid (n = 24), or nondiploid (n = 22, tetraploid and aneuploid). Median follow-up time was 36 months. Results. Diploid tumors were associated with a significantly better actuarial outcome at 4 years, compared with near- diploid tumors, using either biochemical relapse (rising PSA) or a composite end point of a rising PSA or clinical relapse (16% versus 52% relapse, P < 0.05, log-rank). Moreover, patients who had nondiploid tumors had the worst prognosis (77% relapse, composite end point). No significant difference was observed between diploid and near-diploid neoplasms regarding actuarial local control, freedom from metastasis, freedom from clinical relapse, or overall survival time. A Cox proportional hazards model, using the composite end point of a rising PSA or relapse, was performed with ploidy categorized as diploid, near-diploid, and nondiploid: pretreatment PSA, DNA ploidy, and tumor grade were found to be independent prognostic factors. When ploidy was categorized as diploid or near-diploid (nondiploid tumors excluded), pretreatment serum PSA and DNA ploidy were independent predictors of outcome. Ploidy remained an independent prognostic factor even when nondiploid tumors were excluded. Conclusions. These data show that patients who have near- diploid tumors have an intermediate prognosis between the more favorable diploid tumors and the less favorable nondiploid tumors.

AB - Background. DNA ploidy is a significant prognostic factor in patients with prostate cancer. Using DNA/nuclear protein flow cytometry, a subpopulation of tumors with near-diploid DNA is identifiable. The prognostic significance of near-diploidy was examined. Methods. Paraffin-embedded formalin fixed prostate tumor tissue from patients treated at M. D. Anderson Cancer Center with external beam radiation therapy was processed for DNA/nuclear protein flow cytometry. All patients had pretreatment and follow-up serum prostate specific antigen (PSA) levels. Seventy-six specimens were suitable for flow cytometric analysis. Tumors were classified as either diploid (n = 30), near- diploid (n = 24), or nondiploid (n = 22, tetraploid and aneuploid). Median follow-up time was 36 months. Results. Diploid tumors were associated with a significantly better actuarial outcome at 4 years, compared with near- diploid tumors, using either biochemical relapse (rising PSA) or a composite end point of a rising PSA or clinical relapse (16% versus 52% relapse, P < 0.05, log-rank). Moreover, patients who had nondiploid tumors had the worst prognosis (77% relapse, composite end point). No significant difference was observed between diploid and near-diploid neoplasms regarding actuarial local control, freedom from metastasis, freedom from clinical relapse, or overall survival time. A Cox proportional hazards model, using the composite end point of a rising PSA or relapse, was performed with ploidy categorized as diploid, near-diploid, and nondiploid: pretreatment PSA, DNA ploidy, and tumor grade were found to be independent prognostic factors. When ploidy was categorized as diploid or near-diploid (nondiploid tumors excluded), pretreatment serum PSA and DNA ploidy were independent predictors of outcome. Ploidy remained an independent prognostic factor even when nondiploid tumors were excluded. Conclusions. These data show that patients who have near- diploid tumors have an intermediate prognosis between the more favorable diploid tumors and the less favorable nondiploid tumors.

KW - DNA

KW - flow cytometry

KW - nuclear protein

KW - ploidy

KW - prostate cancer

KW - radiation therapy

UR - http://www.scopus.com/inward/record.url?scp=0028288529&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028288529&partnerID=8YFLogxK

M3 - Article

C2 - 7511039

AN - SCOPUS:0028288529

VL - 73

SP - 1895

EP - 1903

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 7

ER -